Surmodics, Inc. (SRDX) Financial Ratios
27 years of historical data (1998–2024) · Healthcare · Medical - Devices
EV/EBITDA
↑
200.60
↑+132% vs avg
5yr avg: 86.42
30Y Low6.6·High84.3
P/FCF
↑
N/A
—
5yr avg: 65.54
30Y Low9.6·High123.8
P/B Ratio
↑
5.12
+17% vs avg
5yr avg: 4.39
30Y Low1.1·High12.8
ROE
↓
-9.7%
↑-67% vs avg
5yr avg: -5.8%
30Y Low-22%·High24%
Debt/EBITDA
↑
10.90
↑+195% vs avg
5yr avg: 3.70
30Y Low0.6·High10.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SRDX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Surmodics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $615M | $549M | $450M | $423M | $778M | $537M | $630M | $982M | $415M | $398M | $290M |
| Enterprise Value | $612M | $546M | $438M | $419M | $760M | $507M | $600M | $959M | $399M | $373M | $235M |
| P/E Ratio → | -52.41 | — | — | — | 185.33 | 478.60 | 83.16 | — | 106.90 | 39.59 | 21.62 |
| P/S Ratio | 4.87 | 4.35 | 3.40 | 4.23 | 7.40 | 5.67 | 6.30 | 12.08 | 5.68 | 5.57 | 4.69 |
| P/B Ratio | 5.12 | 4.62 | 3.75 | 3.90 | 5.55 | 4.10 | 5.14 | 9.04 | 3.72 | 3.72 | 3.11 |
| P/FCF | — | — | 59.28 | — | 85.38 | 51.98 | 488.57 | 49.21 | 54.46 | 23.43 | 22.08 |
| P/OCF | 2477.87 | 2213.12 | 42.82 | — | 50.54 | 38.36 | 78.41 | 28.84 | 29.54 | 15.81 | 19.32 |
P/E links to full P/E history page with 30-year chart
SRDX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Surmodics, Inc.'s enterprise value stands at 200.6x EBITDA, 132% above its 5-year average of 86.4x. The Healthcare sector median is 14.4x, placing the stock at a 1294% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.33 | 3.31 | 4.19 | 7.23 | 5.35 | 5.99 | 11.79 | 5.45 | 5.22 | 3.79 |
| EV / EBITDA | 200.60 | 179.07 | 30.59 | — | 51.65 | 84.34 | 43.53 | — | 31.48 | 17.15 | 10.72 |
| EV / EBIT | — | — | 73.33 | — | 114.23 | — | 87.49 | — | 54.03 | 17.31 | 12.29 |
| EV / FCF | — | — | 57.69 | — | 83.46 | 49.04 | 465.03 | 48.04 | 52.29 | 21.96 | 17.85 |
SRDX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Surmodics, Inc. earns an operating margin of -4.5%. Operating margins have expanded from -22.1% to -4.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -9.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.8% | 73.8% | 46.0% | 29.0% | 39.2% | 30.9% | 33.5% | 32.4% | 40.9% | 58.8% | 60.0% |
| Operating Margin | -4.5% | -4.5% | 3.9% | -22.1% | 6.4% | -1.3% | 6.5% | -10.8% | 9.7% | 23.6% | 30.8% |
| Net Profit Margin | -9.2% | -9.2% | -1.2% | -27.3% | 4.0% | 1.2% | 7.6% | -5.5% | 5.4% | 14.0% | 21.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.7% | -9.7% | -1.3% | -22.0% | 3.1% | 0.9% | 6.6% | -4.0% | 3.6% | 10.0% | 14.0% |
| ROA | -6.3% | -6.3% | -0.9% | -15.5% | 2.3% | 0.7% | 4.7% | -3.0% | 2.9% | 8.6% | 13.1% |
| ROIC | -3.7% | -3.7% | 3.6% | -14.6% | 4.4% | -1.0% | 5.5% | -7.3% | 6.0% | 21.1% | 30.8% |
| ROCE | -3.5% | -3.5% | 3.6% | -15.2% | 4.3% | -0.9% | 4.8% | -6.9% | 5.7% | 15.4% | 19.4% |
SRDX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Surmodics, Inc. carries a Debt/EBITDA ratio of 10.9x, which is highly leveraged (231% above the sector average of 3.3x). The company holds a net cash position — cash of $36M exceeds total debt of $33M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.28 | 0.14 | 0.10 | 0.03 | — | — | — | — | — |
| Debt / EBITDA | 10.90 | 10.90 | 2.32 | — | 0.93 | 0.63 | — | — | — | — | — |
| Net Debt / Equity | — | -0.02 | -0.10 | -0.04 | -0.12 | -0.23 | -0.25 | -0.21 | -0.15 | -0.23 | -0.60 |
| Net Debt / EBITDA | -0.94 | -0.94 | -0.84 | — | -1.19 | -5.05 | -2.20 | — | -1.31 | -1.15 | -2.54 |
| Debt / FCF | — | — | -1.58 | — | -1.92 | -2.94 | -23.54 | -1.17 | -2.17 | -1.47 | -4.23 |
| Interest Coverage | -1.12 | -1.12 | 1.71 | -36.61 | 21.47 | -9.93 | 45.11 | — | — | — | — |
Net cash position: cash ($36M) exceeds total debt ($33M)
SRDX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Surmodics, Inc.'s current ratio of 3.96x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.22x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.80x to 3.96x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.96 | 3.96 | 3.62 | 1.80 | 2.36 | 4.58 | 4.03 | 2.32 | 6.21 | 5.78 | 14.42 |
| Quick Ratio | 3.22 | 3.22 | 3.00 | 1.43 | 2.13 | 4.27 | 3.81 | 2.21 | 5.85 | 5.42 | 13.79 |
| Cash Ratio | 1.95 | 1.95 | 1.89 | 0.59 | 1.30 | 3.23 | 2.74 | 1.84 | 4.93 | 4.63 | 11.83 |
| Asset Turnover | — | 0.71 | 0.71 | 0.63 | 0.54 | 0.56 | 0.63 | 0.50 | 0.54 | 0.54 | 0.62 |
| Inventory Turnover | 2.18 | 2.18 | 4.82 | 6.00 | 9.45 | 10.98 | 14.78 | 13.69 | 12.30 | 8.22 | 8.32 |
| Days Sales Outstanding | — | 67.37 | 65.80 | 88.37 | 79.55 | 62.23 | 64.78 | 39.84 | 38.99 | 38.70 | 44.10 |
SRDX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Surmodics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.5% | 0.2% | 1.2% | — | 0.9% | 2.5% | 4.6% |
| FCF Yield | — | — | 1.7% | — | 1.2% | 1.9% | 0.2% | 2.0% | 1.8% | 4.3% | 4.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.1% | 7.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.1% | 7.2% |
| Shares Outstanding | — | $14M | $14M | $14M | $14M | $14M | $14M | $13M | $13M | $13M | $13M |
Peer Comparison
Compare SRDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SRDXYou | $615M | -52.4 | 200.6 | — | 73.8% | -4.5% | -9.7% | -3.7% | 10.9 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 LAKE | $106M | -4.5 | — | — | 41.1% | -5.5% | -13.4% | -5.1% | — |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 ITGR | $3B | 30.4 | 13.1 | 28.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 PCVX | $7B | -9.1 | — | — | — | — | -25.6% | -24.2% | — |
 CNMD | $1B | 25.2 | 10.2 | 7.8 | 52.8% | 10.3% | 4.7% | 5.8% | 4.3 |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
See SRDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRDX vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonSRDX — Frequently Asked Questions
Quick answers to the most common questions about buying SRDX stock.
What is Surmodics, Inc.'s P/E ratio?
Surmodics, Inc.'s current P/E ratio is -52.4x. The historical average is 59.1x.
What is Surmodics, Inc.'s EV/EBITDA?
Surmodics, Inc.'s current EV/EBITDA is 200.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.6x.
What is Surmodics, Inc.'s ROE?
Surmodics, Inc.'s return on equity (ROE) is -9.7%. The historical average is 5.4%.
Is SRDX stock overvalued?
Based on historical data, Surmodics, Inc. is trading at a P/E of -52.4x. Compare with industry peers and growth rates for a complete picture.
What are Surmodics, Inc.'s profit margins?
Surmodics, Inc. has 73.8% gross margin and -4.5% operating margin.
How much debt does Surmodics, Inc. have?
Surmodics, Inc.'s Debt/EBITDA ratio is 10.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.